HeLa Xenograft Model Service for Cervical Cancer

The HeLa Xenograft Model Service for Cervical Cancer provides a robust, well-characterized preclinical platform for evaluating therapeutic efficacy against HPV-driven cervical malignancies. Alfa Cytology delivers comprehensive, customizable HeLa xenograft model development and pharmacological testing services, enabling researchers to accelerate preclinical discovery with reproducible, high-quality tumor models tailored to their specific study objectives.

Overview of HeLa Xenograft Model for Cervical Cancer

The HeLa xenograft model is a cell line-derived tumor model generated by implanting HeLa cells---an immortalized human cervical adenocarcinoma line---into immunodeficient mice. Originally isolated in 1951 from a patient with cervical adenocarcinoma, HeLa cells harbor integrated HPV-18 DNA, which drives constitutive expression of the E6 and E7 oncoproteins. These viral proteins inactivate p53 and pRB tumor suppressor pathways, respectively, resulting in uncontrolled proliferation, genomic instability, and robust tumorigenicity. When engrafted subcutaneously or orthotopically into immunocompromised hosts such as nude or NOD-SCID mice, HeLa cells reliably form palpable tumors within 1--3 weeks, exhibiting epithelial morphology, high mitotic index, and preserved HPV-associated molecular signatures. The model has been extensively validated across preclinical studies for antiviral therapies, cytotoxic agents, targeted inhibitors, and combination regimens, making it one of the most widely utilized platforms for cervical cancer drug development.

HeLa xenografts retain key histopathological and molecular characteristics of the original tumor, including cytokeratin expression confirming epithelial lineage, elevated telomerase activity, and hypertriploid karyotype (76--80 chromosomes). The model supports both subcutaneous and orthotopic implantation strategies; while subcutaneous engraftment offers simplicity and ease of tumor monitoring, orthotopic implantation into the cervical region more faithfully recapitulates the tumor microenvironment, enabling studies of local invasion, metastatic dissemination, and peritoneal spread. Due to its rapid growth kinetics, high engraftment success rate, and well-defined molecular drivers, the HeLa xenograft model serves as an indispensable tool for preclinical pharmacology, biomarker identification, and mechanism-of-action studies in cervical cancer research.

Figure 1. HeLa cell lines from different laboratories showed varied and evolving genotypes. (Liu, Y, et al., 2019)

Cell Line Information: HeLa

HeLa is the first established human immortal cell line, derived from an adenocarcinoma of the cervix. The line is HPV-18 positive and exhibits epithelial morphology with adherent growth properties. Its robust proliferation rate, susceptibility to transfection, and well-characterized oncogenic drivers make it a cornerstone model for cervical cancer preclinical research.

Our Services

Alfa Cytology offers end-to-end HeLa xenograft model services encompassing cell line authentication, immunodeficient mouse procurement, tumor implantation, in-life monitoring, and comprehensive endpoint analysis. Our experienced team ensures rigorous quality control at every stage---from STR profiling of HeLa cells and pathogen screening to standardized tumor measurement protocols and histopathological evaluation---providing researchers with publication-ready data packages and reliable preclinical insights for their cervical cancer therapeutic programs.

Workflow of HeLa Xenograft Model Construction

The construction of a HeLa xenograft model follows a standardized, multi-step workflow designed to ensure reproducible tumor growth and reliable pharmacological readouts. Each phase integrates quality assurance measures to maintain model integrity and data validity throughout the study duration.

1. Cell Line Preparation and Authentication HeLa cells are revived from cryopreserved stocks and expanded under adherent culture conditions in supplemented EMEM. Prior to implantation, cells undergo STR authentication to confirm identity, mycoplasma testing to exclude contamination, and viability assessment to ensure >95% live cell population.
2. Host Selection and Acclimatization Immunodeficient mice (nude, SCID, or NSG strains) are selected based on study objectives and engraftment requirements. Animals are acclimatized for 5--7 days under controlled environmental conditions with standardized diet and water ad libitum.
3. Tumor Cell Inoculation Exponentially growing HeLa cells are harvested, washed, and resuspended in serum-free medium mixed with Matrigel or PBS at a defined concentration (typically 1x10^6 to 5x10^6 cells per 100--200 uL). The cell suspension is injected subcutaneously into the flank or orthotopically into the cervical region using a sterile insulin syringe.
4. Tumor Establishment and Monitoring Mice are monitored daily for general health and weighed twice weekly. Tumor dimensions are measured with digital calipers beginning when nodules become palpable, and tumor volume is calculated using the modified ellipsoid formula (length x width^2 x 0.5).
5. Study Cohort Randomization Once tumors reach a predetermined volume (typically 100--200 mm^3), mice are randomized into treatment and control groups to minimize inter-group variability. Randomization is performed using stratified algorithms based on tumor size and body weight.
6. Treatment Administration and In-Life Assessment Test compounds are administered via the designated route (oral gavage, intraperitoneal, intravenous, or intratumoral) according to the study protocol. Tumor growth, body weight, and clinical signs are recorded at defined intervals throughout the treatment period.
7. Endpoint Analysis and Tissue Collection At study termination, tumors are excised, weighed, and photographed. Tissues are fixed in formalin for H&E and immunohistochemistry (IHC) analysis, snap-frozen for molecular profiling, or dissociated for flow cytometry and cell analyses as required.

Figure 2. HeLa xenograft model construction workflow.

Case Study-HeLa Xenograft Model Development

In a recent preclinical engagement, Alfa Cytology successfully established subcutaneous HeLa xenografts in NOD-SCID mice to evaluate a novel therapeutic candidate targeting the HPV E6/E7 axis. Tumors achieved palpable size within 10--14 days post-inoculation and demonstrated consistent growth kinetics across all enrolled animals. The treatment arm exhibited dose-dependent tumor growth inhibition compared to vehicle controls, with corresponding reductions in Ki-67 proliferation index and induction of apoptotic markers observed by immunohistochemistry. Detailed efficacy data, pharmacokinetic correlations, and histopathological findings are available upon formal inquiry. Please contact our scientific team to request the full case study report and discuss how these data may inform your preclinical program.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational flexibility to deliver preclinical xenograft services that meet the highest standards of data quality and regulatory compliance. Our dedicated team of oncology specialists ensures seamless execution from study design to final report.

• Extensive experience in HeLa and cervical cancer xenograft model development with proven engraftment success rates.
• Comprehensive cell line authentication (STR profiling) and pathogen screening to ensure model integrity and reproducibility.
• Customizable study designs including subcutaneous, orthotopic, and metastatic model configurations tailored to your therapeutic hypothesis.
• Real-time tumor monitoring with digital caliper measurements and optional non-invasive imaging modalities for longitudinal assessment.
• Full-spectrum endpoint analysis encompassing tumor histopathology, immunohistochemistry, biomarker profiling, and pharmacokinetic integration.
• Dedicated project management with transparent communication, milestone tracking, and rapid turnaround times to accelerate your preclinical timeline.

Contact Us

Ready to advance your cervical cancer preclinical program with a validated HeLa xenograft model? Reach out to Alfa Cytology today to discuss your study requirements, request a customized proposal, or schedule a consultation with our scientific team. Please reach out to us today via our inquiry form or email to learn more about our HeLa Xenograft Model services.

For research use only. Not intended for any clinical use.